COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

Search

Novo Nordisk A-S (Class B)

Uždarymo kaina

490.95 3.11

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

486.95

Max

492.1

Pagrindiniai rodikliai

By Trading Economics

Pajamos

804M

29B

Pardavimai

-7.6B

78B

P/E

Sektoriaus vid.

20.239

51.198

Pelnas, tenkantis vienai akcijai

6.53

Dividendų pajamingumas

3.33

Pelno marža

37.182

Darbuotojai

77,406

EBITDA

4.1B

39B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+9.53% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.33%

2.40%

Kitas uždarbis

2025-08-06

Kitas dividendų mokėjimo data

2025-08-18

Kita Ex Dividend data

2025-08-14

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-8B

2T

Ankstesnė atidarymo kaina

487.84

Ankstesnė uždarymo kaina

490.95

Novo Nordisk A-S (Class B) Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-16 11:36; UTC

Svarbiausios naujienos

Novo Nordisk CEO to Step Down Amid Market Challenges

2025-05-12 09:36; UTC

Pagrindinės rinkos jėgos

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

2025-05-07 11:29; UTC

Svarbiausios naujienos
Uždarbis
Pagrindinės rinkos jėgos

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

2025-05-07 07:05; UTC

Uždarbis

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales -- Update

2025-05-07 06:19; UTC

Uždarbis

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales

2025-06-03 15:03; UTC

Įsigijimai, susijungimai, perėmimai

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

2025-05-29 01:00; UTC

Svarbiausios naujienos

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

2025-05-20 14:08; UTC

Uždarbis

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

2025-05-20 07:43; UTC

Rinkos pokalbiai

Novo Nordisk Guidance at Risk After CEO News -- Market Talk

2025-05-16 18:35; UTC

Svarbiausios naujienos

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

2025-05-16 17:34; UTC

Svarbiausios naujienos

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 2nd Update

2025-05-16 13:42; UTC

Karštos akcijos

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

2025-05-16 13:27; UTC

Rinkos pokalbiai

Novo Nordisk CEO Departure Comes as a Surprise -- Market Talk

2025-05-16 13:15; UTC

Svarbiausios naujienos

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- Update

2025-05-16 12:17; UTC

Uždarbis

Novo Nordisk Chairman: No Link Between CEO Change and Other Recent Exec Departures

2025-05-12 22:14; UTC

Svarbiausios naujienos

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

2025-05-12 18:45; UTC

Svarbiausios naujienos

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

2025-05-12 12:07; UTC

Rinkos pokalbiai

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

2025-05-12 07:20; UTC

Rinkos pokalbiai

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

2025-05-07 15:13; UTC

Uždarbis

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

2025-05-07 13:56; UTC

Uždarbis

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

2025-05-07 13:45; UTC

Uždarbis

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

2025-05-07 11:25; UTC

Uždarbis

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

2025-05-07 11:18; UTC

Uždarbis

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

2025-05-07 09:55; UTC

Uždarbis

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Disney, and More -- Barrons.com

2025-05-07 09:36; UTC

Uždarbis

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Tesla, and More -- Barrons.com

2025-05-07 09:04; UTC

Uždarbis
Karštos akcijos

Stocks to Watch Wednesday: Disney, Uber, Super Micro -- WSJ

2025-05-07 08:10; UTC

Rinkos pokalbiai

Novo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk

2025-05-07 08:08; UTC

Rinkos pokalbiai

Novo Nordisk's Downgraded Guidance Assumes Large Wegovy Uplift in 2H -- Market Talk

2025-05-07 07:11; UTC

Rinkos pokalbiai
Uždarbis

Novo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk

Akcijų palyginimas

Kainos pokytis

Novo Nordisk A-S (Class B) Prognozė

Kainos tikslas

By TipRanks

9.53% į viršų

12 mėnesių prognozė

Vidutinis 1,162.73 DKK  9.53%

Aukščiausias 1,550 DKK

Žemiausias 720 DKK

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Novo Nordisk A-S (Class B) kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

7

Pirkti

2

Laikyti

2

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.